This was the ADR's second consecutive day of gains.

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...

DUBAI, UAE - - 28 January 2025 - AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been ...

The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

When we think of artificial intelligence (AI), data science and the potential real-world impact of these rapidly developing fields, we tend to look to the future—particularly when it comes to ...

Copies of AstraZeneca Plc’s Calquence tablets proposed by MSN Laboratories Pvt. Ltd. infringe two patents for the blood-cancer treatment, according to a federal lawsuit filed six months after MSN ...